AZD9496 First Time in Patients Ascending Dose Study
Completed · Phase 1
Conditions studied: ER+ HER2- Advanced Breast Cancer
In brief
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of patients. The study will determine the maximum tolerated dose. In addition, expansion cohort(s) at potential therapeutic dose(s) in patients with or without ESR1 mutations will be enrolled to further determine the safety, tolerability, pharmacokinetics and biological activity of AZD9496
Key facts
- Study ID
- NCT02248090
- Run by
- AstraZeneca
- People needed
- 45
- Starts
- 2014-10-22
- Expected to finish
- 2019-04-03
- Last updated by the study team
- 2019-06-24
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Florida Cancer Specialists — Sarasota, Florida, United States
- Research Site — New York, New York, United States
- Sarah Cannon — Nashville, Tennessee, United States
- Seoul National Univ. Hospital — Seoul, South Korea
- Research Site — Cambridge, United Kingdom
- Christie — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.